Geovax Labs (GOVX) Stock Price, Quote & News

Company Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tu...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 384 7220

Fax: 678 384 7281

Website: www.geovax.com

Address:

1900 Lake Park Drive, Suite 380, Smyrna, United States

cheapostock Dec. 31 at 5:05 PM

no movement and continue to watch these next weeks... no new plays!!! $GOVX $TOVX $NCNA $ICU

1 · Reply

To_De_Moon Dec. 31 at 1:04 PM

$GOVX

0 · Reply

To_De_Moon Dec. 31 at 1:02 PM

$GOVX mega green candle!

0 · Reply

DeezNuttz Dec. 30 at 9:34 PM

$GOVX

0 · Reply

To_De_Moon Dec. 29 at 8:18 PM

$GOVX finishing green

0 · Reply

BKEBurgy Dec. 29 at 6:25 PM

$GOVX 20k shares at $0.1685 Extremely low risk- high reward play 🫡🫡

0 · Reply

cheapostock Dec. 29 at 5:07 PM

$VIVK mgmt been so quiet since down fall began... and now with this being in OTC, price will be volatile and it's damn sure it will never reach beyond 20c! So its waste of time!!!! move to $IVP $GOVX $TOVX

1 · Reply

To_De_Moon Dec. 28 at 3:12 PM

$GOVX

0 · Reply

truthdotphd Dec. 26 at 7:49 PM

$GOVX it's gonna jump crazy

0 · Reply

Mark_Etmaker Dec. 26 at 7:43 PM

$GOVX 🐂🐂📈

0 · Reply

GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

Jul 28, 2025, 7:43 PM EDT - 5 months ago

GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript

May 1, 2025, 8:58 PM EDT - 8 months ago

GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript

Mar 27, 2025, 8:53 PM EDT - 9 months ago

GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript

Dec 9, 2024, 9:00 AM EST - 1 year ago

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Nov 26, 2024, 9:00 AM EST - 1 year ago

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

Nov 12, 2024, 11:33 PM EST - 1 year ago

GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:00 PM EST - 1 year ago

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 9:00 AM EST - 1 year ago

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

Oct 2, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 3, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 8:59 PM EDT - 1 year ago

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Aug 20, 2024, 8:09 AM EDT - 1 year ago

GeoVax's stock slides 20% after company raises $8.5 million in stock sale

Aug 20, 2024, 7:45 AM EDT - 1 year ago

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS IMRN

Aug 19, 2024, 7:30 AM EDT - 1 year ago

GeoVax's stock soars 54% to lead rally in companies developing mpox treatments

Aug 15, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Aug 15, 2024, 8:36 AM EDT - 1 year ago

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

EBS SIGA

Aug 10, 2024, 6:15 AM EDT - 1 year ago

GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 9:00 AM EDT - 1 year ago

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

Aug 6, 2024, 4:00 PM EDT - 1 year ago

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 10:15 AM EDT - 1 year ago

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

May 14, 2024, 8:01 PM EDT - 1 year ago

GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript

Apr 4, 2024, 12:30 PM EDT - 1 year ago

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Mar 28, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

Mar 12, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Present at the 36th Annual Roth Conference

Mar 6, 2024, 9:00 AM EST - 1 year ago

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Mar 1, 2024, 2:34 AM EST - 1 year ago

GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:00 PM EST - 1 year ago

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Feb 22, 2024, 9:00 AM EST - 2 years ago

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

Feb 19, 2024, 9:00 AM EST - 2 years ago

GeoVax to Present at the 2024 BIO CEO & Investor Conference

Feb 13, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Multiple Patent Issuances and Allowances

Feb 6, 2024, 9:00 AM EST - 2 years ago

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Jan 29, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Jan 8, 2024, 9:00 AM EST - 2 years ago

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

Jan 4, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

Jan 3, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Issuance of Malaria Vaccine Patent

Dec 27, 2023, 9:00 AM EST - 2 years ago

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

Dec 19, 2023, 9:00 AM EST - 2 years ago

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Nov 30, 2023, 4:30 PM EST - 2 years ago

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

Nov 29, 2023, 9:00 AM EST - 2 years ago

GeoVax to Participate in Upcoming December Investor Events

Nov 28, 2023, 9:00 AM EST - 2 years ago

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Nov 14, 2023, 9:00 AM EST - 2 years ago

Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Nov 8, 2023, 9:26 PM EST - 2 years ago

GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:00 PM EST - 2 years ago

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 30, 2023, 9:00 AM EDT - 2 years ago

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Oct 25, 2023, 9:00 AM EDT - 2 years ago

GeoVax to Participate in Upcoming November Investor and Industry Events

Oct 24, 2023, 9:00 AM EDT - 2 years ago

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

Oct 9, 2023, 9:00 AM EDT - 2 years ago

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Oct 5, 2023, 9:00 AM EDT - 2 years ago

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

cheapostock Dec. 31 at 5:05 PM

no movement and continue to watch these next weeks... no new plays!!! $GOVX $TOVX $NCNA $ICU

1 · Reply

To_De_Moon Dec. 31 at 1:04 PM

$GOVX

0 · Reply

To_De_Moon Dec. 31 at 1:02 PM

$GOVX mega green candle!

0 · Reply

DeezNuttz Dec. 30 at 9:34 PM

$GOVX

0 · Reply

To_De_Moon Dec. 29 at 8:18 PM

$GOVX finishing green

0 · Reply

BKEBurgy Dec. 29 at 6:25 PM

$GOVX 20k shares at $0.1685 Extremely low risk- high reward play 🫡🫡

0 · Reply

cheapostock Dec. 29 at 5:07 PM

1 · Reply

To_De_Moon Dec. 28 at 3:12 PM

$GOVX

0 · Reply

truthdotphd Dec. 26 at 7:49 PM

$GOVX it's gonna jump crazy

0 · Reply

Mark_Etmaker Dec. 26 at 7:43 PM

$GOVX 🐂🐂📈

0 · Reply

truthdotphd Dec. 26 at 6:07 PM

$GOVX $1.0

0 · Reply

cheapostock Dec. 26 at 3:29 PM

watchlist for next week $VIVK $IVP $GOVX $TOVX $ICU

0 · Reply

vlentini Dec. 26 at 2:16 PM

$GOVX Un cesso di titolo,state alla larga,comprasse il CEO e il consiglio di amministrazione,loro non posseggono nemmeno un'azione,aspettano i polli!!!

0 · Reply

Ueberschlaefer Dec. 26 at 2:00 PM

$GOVX you guys are still pushing this wet turd up a hill... why? anyone who had taken your previous advice would've been smoked on this ticker. would've taken massive losses. your price targets are all garbage. what is the point in pushing this shit on retailers?

0 · Reply

ZacksResearch Dec. 26 at 10:14 AM

$GOVX: Deep value… or falling knife? ⚠️ Shares trade at a 12-month trailing P/B of 1.10 — well below the industry average of 3.68 and under its own 5-year mean of 1.48. But the stock is down 71.1% in just three months, and loss estimates have moved the wrong way fast 📉. • 2025 loss estimate widened from $1.42 to $1.34 per share • 2026 loss estimate jumped from an 84-cent loss to $1.33 per share over the past 60 days So is this a contrarian value setup… or a warning sign to stay cautious? See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/GOVX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-26338&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_26338

1 · Reply

OrangeOrder Dec. 25 at 9:37 AM

$GOVX Upside depends on translating ambition into measurable cadence, with macro volatility magnifying operational missteps. The upside case requires evidence, not projection.

2 · Reply